Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

Ponatinib plus blinatumomab significantly improves 24-month event-free survival to 86% in adult Ph-positive ALL compared to 67% with imatinib and chemotherapy.

• Why it matters: Improved outcomes in Philadelphia-positive ALL are crucial, as traditional treatments have limited success, especially in adult populations. This work addresses the need for more effective frontline therapies that can enhance survival and reduce relapse.
• What they did: The trial randomly assigned 236 adults with Ph-positive ALL to receive either ponatinib plus blinatumomab or imatinib plus chemotherapy, with a median follow-up of 23.7 months, measuring event-free survival and molecular responses.
• The result: The intervention group showed higher complete hematologic response (94% vs. 79%), molecular response after consolidation (71% vs. 49%), and lower relapse incidence (5% vs. 13%), indicating the chemotherapy-free approach's superiority.